Hormonal receptor, human epidermal growth factor receptor-2, and ki67 discordance between primary breast cancer and paired metastases: Clinical impact

Toni Ibrahim, Alberto Farolfi, Emanuela Scarpi, Laura Mercatali, Laura Medri, Marianna Ricci, Oriana Nanni, Luigi Serra, Dino Amadori

Research output: Contribution to journalArticle

Abstract

Objective: As hormone receptor and human epidermal growth factor receptor-2 (HER-2) expression in primary breast tumors frequently differs from that of paired metastases, we first evaluated the discordance rate (DR) of estrogen receptor (ER), progesterone receptor (PgR), HER-2, and Ki67 in breast cancer patients and then assessed the discordance effect on prognosis. Methods: Of 145 cases reviewed, 120 with samples available from both primary tumors and paired metastases were included in the study. For each receptor, the DR was calculated as the proportion of discordant cases with respect to the total number of patients. Results: A change in ER status was observed in 19 cases (DR 16.4%), while PgR status was modified in 48 cases (DR 41.7%). HER-2 was altered in 21 cases (DR 17.5%), and Ki67 in 33 patients (DR 38.8%). Patients with Ki67

Original languageEnglish
Pages (from-to)150-157
Number of pages8
JournalOncology
Volume84
Issue number3
DOIs
Publication statusPublished - Jan 2013

Keywords

  • Advanced breast cancer prognosis
  • Discordance
  • Hormone receptors
  • Human epidermal growth factor receptor-2
  • Ki67
  • Metastasis biopsy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Hormonal receptor, human epidermal growth factor receptor-2, and ki67 discordance between primary breast cancer and paired metastases: Clinical impact'. Together they form a unique fingerprint.

  • Cite this